|
1
|
Nicholson AG, Tsao MS, Beasley MB, Borczuk
AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S,
et al: The 2021 WHO classification of lung tumors: impact of
advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schoenfeld AJ, Rizvi H, Bandlamudi C,
Sauter JL, Travis WD, Rekhtman N, Plodkowski AJ, Perez-Johnston R,
Sawan P, Beras A, et al: Clinical and molecular correlates of PD-L1
expression in patients with lung adenocarcinomas. Ann Oncol.
31:599–608. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Di Federico A, Stumpo S, Mantuano F, De
Gilglio A, Lo Bianco F Pecci F, Alessi JV, Wang X, Sperandi F,
Melotti B, et al: Long-term overall survival with dual CTLA-4 and
PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in
patients with advanced non-small-cell lung cancer: A systematic
review and reconstructed individual patient data meta-analysis.
Lancet Oncol. 26:1443–1453. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu L, Li C and Lu H: Invasive mucinous
adenocarcinoma of the lung. Transl Cancer Res. 8:2924–2932. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liang Y, Maeda O, Kondo C, Nishida K and
Ando Y: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the
clinical outcomes of immune checkpoint inhibitors among patients
with lung adenocarcinoma. PLoS One. 19:e03075802024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu M, Zhao X, Wen T and Qu X: Unveiling
the role of KRAS in tumor immune microenvironment. Biomed
Pharmacother. 171:1160582024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jang YJ, Hyun DG, Choi CM, Lee DH, Kim SW,
Yoon S, Kim WS, Ji W and Lee JC: Optimizing palliative chemotherapy
for advanced invasive mucinous adenocarcinoma of the lung. BMC
Cancer. 21:7312021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SH, Seong H, Lee J, Ahn HY, Cho JS, I
H, Kim YD, Lee MK, Eom JS and Kim MH: The role of local ablative
therapy in patients with advanced invasive mucinous adenocarcinoma
of the lung. J Cancer Res Clin Oncol. 150:4092024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chae YK, Othus M, Patel SP, Gerber DE,
Tanvetyanon T, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, et
al: Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in
rare tumors SWOG/NCI experience: Invasive mucinous or non-mucinous
lepidic adenocarcinoma of the lung (formerly bronchioloalveolar
carcinoma). Ther Adv Med Oncol. 16:175883592412934012024.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu C, Zheng S, Wang Z, Wang S, Wang X,
Yang L, Xu H, Cao Z, Feng X, Xue Q, et al: KRAS-G12D mutation
drives immune suppression and the primary resistance of
anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer
Commun (Lond). 42:828–847. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Frost N, Zhamurashvili T, von Laffert M,
Klauschen F, Ruwwe-Glösenkamp C, Raspe M, Brunn M, Ochsenreither S,
Temmesfeld-Wollbrück B, Suttorp N, et al: Pemetrexed-based
chemotherapy is inferior to pemetrexed-free regimens in thyroid
transcription factor 1 (TTF-1)-Negative, EGFR/ALK-negative lung
adenocarcinoma: A propensity score matched pairs analysis. Clin
Lung Cancer. 21:e607–e621. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seymour L, Bogaerts J, Perrone A, Ford R,
Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et
al: iRECIST: guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yanada H, Yoshida R, Kida R, Nitanai K,
Ikeda M, Nagasue K, Naraoka T, Ueda M, Watanabe T and Shigaki R:
Sotorasib resistance in KRAS G12C-mutant invasive mucinous
adenocarcinoma with implications for VEGF-A. NPJ Precis Oncol.
9:1542025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamakawa H, Takayanagi N, Ishiguro T,
Kagiyama N, Shimizu Y and Sugita Y: A favorable response to
cisplatin, pemetrexed and bevacizumab in two cases of invasive
mucinous adenocarcinoma formerly known as pneumonic-type mucinous
bronchioloalveolar carcinoma. Intern Med. 52:2781–2784. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun XW, Ding YJ, Zhang YY, Chen PL, Yan
YR, Shen JM and Li QY: Favorable response to pemetrexed, cisplatin
and bevacizumab in invasive mucinous adenocarcinoma: A case report
and literature review. Mol Clin Oncol. 9:192–196. 2018.PubMed/NCBI
|
